Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.
The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer.
Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...
The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.
Nivolumab, an immune checkpoint inhibitor lauded for its groundbreaking approach to cancer treatment, marked its 10th ...
The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with resectable NSCLC.
The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...
The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
The FDA greenlighted Bristol Myers Squibb’s Opdivo for use before and after surgery for non-small cell lung cancer. A regimen ...
Cybersecurity software firms saw demand wane slightly during September, but most remain positive they will beat estimates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback